Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
Solid Biosciences (SLDB) Stock Price & Analysis
505 Followers
SLDB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.81 - $15.05
Previous Close$8.56
Volume777.30K
Average Volume (3M)439.38K
Market Cap
$328.53M
Enterprise Value$148.28M
Total Cash (Recent Filing)$206.07M
Total Debt (Recent Filing)$25.82M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Aug 12, 2024EPS Estimate
-$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.93
Shares Outstanding38,379,413
10 Day Avg. Volume525,262
30 Day Avg. Volume439,375
Standard Deviation0.33
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.96
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
$16.17Price Target Upside88.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Solid Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSLDB is on track to initiate patient dosing for SGT-003 in its Phase 1/2 trial, signaling progress in the drug's development.
Financial PerformanceSolid Bio had cash and cash equivalents of approximately $206M, which is sufficient to fund operations into 2026.
Stock RatingAnalyst maintains a Buy rating on SLDB and a 12-month price target of $16 per share based on a risk-adjusted net present value analysis.
Bears Say
Commercial RisksClinical, regulatory, and commercial risks associated with Solid Bio's pipeline products.
EarningsThe company reported no revenue and a net loss of $0.64 per share.
Regulatory RisksClinical, regulatory, and commercial risks are associated with pipeline products.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $1.81 and its highest was $15.05 in the past 12 months.
What is Solid Biosciences’s market cap?
Currently, no data Available
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Aug 12, 2024 which is in 21 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on May 09, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.639 by -$0.001.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -$0.65.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 38,379,414 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.639. Following the earnings report the stock price went up 0.878%.
Which hedge fund is a major shareholder of Solid Biosciences?
Among the largest hedge funds holding Solid Biosciences’s share is Perceptive Advisors LLC. It holds Solid Biosciences’s shares valued at 92M.
---
Solid Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.17 (88.90% Upside)
$16.17 (88.90% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 6.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
74.33%
12-Months-Change
Fundamentals
Return on Equity
-45.75%
Trailing 12-Months
Asset Growth
8.32%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
---
SLDB Stock 12 Month Forecast
Average Price Target
$16.17
▲(88.90% Upside)
Technical Analysis
Best Analysts Covering SLDB
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-35.83%
reiterated a buy rating 25 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -35.83% per trade.
---